Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis

References

• Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242–8.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rosado I, Moutinho V, Jr, DeMatteo RP, Kingham TP, D’Angelica M, Brennan MF. Outcomes of the memorial Sloan Kettering cancer center international general surgical oncology fellowship. J Am Coll Surg. 2016;222(5):961–6.
   PubMed Web of Science ®Google Scholar
• Kehl AS, Corr M, Weisman MH. Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheumatol. 2016;68(2):312–22.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40(8):1357–9.
   PubMed Web of Science ®Google Scholar
• Brockbank J, Stein M, Schentag C, Gladman D. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64(2):188–90.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ohtsuki M, Sano S, Igarashi A, Morita A, Okuyama R, et al. Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol. 2016;43(10):1193–6.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809–12.
   PubMed Web of Science ®Google Scholar
• McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42(6):778–83.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6):960–77.
   PubMed Web of Science ®Google Scholar
• Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006;65(4):453–8.
   PubMed Web of Science ®Google Scholar
• Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003;62(2):120–6.
   PubMed Web of Science ®Google Scholar
• Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis. 2003;62:427–30.
   PubMed Web of Science ®Google Scholar
• Shibata S, Tada Y, Komine M, Hattori N, Osame S, Kanda N, et al. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. J Dermatol Sci. 2009; 53(1):34–9.
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis. 2005;64(8):1145–9.
   PubMed Web of Science ®Google Scholar
• Candia L, Marquez J, Gonzalez C, Santos AM, Londo J, Valle R, et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol. 2006;12(5):226–9.
   PubMed Web of Science ®Google Scholar
• Popescu C, Zofotă S, Bojincă V, Ionescu R. Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis–cross-sectional study and literature review. J Med Life. 2013;6(4):376–82.
   PubMedGoogle Scholar
• Abdel Fattah NS, Hassan HE, Galal ZA, El Okda el SE. Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. BMC Res Notes. 2009;2(1):44.
   PubMedGoogle Scholar
• Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford). 2005;44(8):1056–60.
   PubMed Web of Science ®Google Scholar
• Maejima H, Aki R, Watarai A, Shirai K, Hamada Y, Katsuoka K. Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients. J Dermatol. 2010;37(4):339–45.
   PubMed Web of Science ®Google Scholar
• Bogliolo L, Alpini C, Caporali R, Scirè CA, Moratti R, Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol. 2005;32(3):511–5.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73.
   PubMed Web of Science ®Google Scholar
• Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology (Oxford). 2014;53(9):1676–82.
   PubMed Web of Science ®Google Scholar
• Rocha-Muñoz AD, Ponce-Guarneros M, Gamez-Nava JI, Olivas-Flores EM, Mejía M, Juárez-Contreras P, et al. Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis. J Immunol Res. 2015;2015:151626.
   PubMedGoogle Scholar
• Yin Y, Liang D, Zhao L, Li Y, Liu W, Ren Y, et al. Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One. 2014;9(4):e92449.
   PubMed Web of Science ®Google Scholar
• Reynisdottir G, Karimi R, Joshua V, Olsen H, Hensvold AH, Harju A, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2014;66(1):31–9.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kawada A. Clinical characteristics of Japanese patients with psoriatic arthritis: comparison with East Asian countries. J Dermatol. 2018;45(3):273–8.
   PubMed Web of Science ®Google Scholar
• Galil SM, El-Shafey AM, Hagrass HA, Fawzy F, Sammak AE. Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. Int J Rheum Dis. 2016;19(4):377–84.
   PubMed Web of Science ®Google Scholar
• Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68(1):69–74.
   PubMed Web of Science ®Google Scholar
• Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis. 2011;70(1):4–7.
   PubMed Web of Science ®Google Scholar
• Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 2007;66(3):302–7.
   PubMed Web of Science ®Google Scholar
• Lv Q, Yin Y, Li X, Shan G, Wu X, Liang D, et al. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS One. 2014;9(2):e89442.
   PubMed Web of Science ®Google Scholar